Key result
Blood pressure lowering reduces recurrent stroke ~28% in patients with prior stroke or TIA.
Why the study?
Prior blood pressure treatment trials focused on primary stroke prevention, leaving controversy over whether long-term blood pressure lowering after a stroke or transient ischaemic attack carries similar secondary prevention benefits.
Answers are grounded in this paper and cite their sources.
Editorial review shows blood pressure lowering reduces recurrent stroke risk in patients with prior stroke or TIA, indicating benefits across both hypertensive and normotensive ranges.
JRAAS 2001;2:153–5 All of the treatment trials in high blood pressure (BP) have shown major reductions in the number of people developing strokes, and this reduction for a given BP appears to be equivalent to the epidemiological risk of that elevation in BP, a remarkable achievement, if true, as the risk of stroke is reversed in a very few years of treatment. However, all these studies have been primary prevention studies and there has, until now, remained some controversy over whether the long-term lowering of BP following a stroke carries similar benefits. It was therefore with great anticipation that the results of the PROGRESS study (Perindopril Protection Against Recurrent Stroke Study), were presented at the European Society of Hypertension Meeting in Milan in June 2001. The results clearly demonstrated a major benefit in stroke reduction by lowering BP in people with a previous history of stroke or transient ischaemic attack (TIA). Importantly, this benefit was throughout the range of BP; in other words both normotensive and hypertensive individuals who had suffered a stroke or TIA benefited from BP-lowering. Increasing BP is the most important contributory factor to primary stroke. Epidemiological studies show a continuous and graded relationship between BP and the risk of primary stroke, and there is no evidence of any lower BP threshold,below which further reductions in BP have no effect on stroke risk. Treatment trials have now clearly demonstrated that a prolonged reduction in BP of 10–12/5–6 mmHg for just a few years reduces the incidence of primary stroke by 35–40%. This is very similar to those predicted from the observational epidemiological studies. Accumulating evidence suggests that there is a similar relationship between BP and secondary (or recurrent) stroke as that of primary stroke. Analysis of the data from the UK-TIA aspirin trial, which involved 2435 individuals with a history of TIA or minor stroke followed up for four years, showed that BP level was an important determinant of recurrent stroke, not only in hypertensive, but also in normotensive individuals. Indeed, there was a direct and continuous relationship between the usual levels of BP and subsequent risk of recurrent stroke (Figure 1). This relationship was independent of age, sex, smoking history and aspirin use. Some supportive evidence on the role of BP in the secondary prevention of stroke comes from treatment trials.A recent meta-analysis of nine randomised, controlled trials in 6752 patients with prior stroke or TIA showed that BP-lowering treatments reduced the incidence of recurrent stroke by 28%. However, in this meta-analysis,one study, the PATS (Post-stroke Antihypertensive Treatment Study), accounted for 75% of the individuals entered into the meta-analysis. The results, therefore, of the meta-analysis were essentially representative of the PATS results. PATS was a ranEditorial review
No takes yet. Share an insight, caveat, or question.
He et al. (2001) conducted an editorial in Previous stroke or transient ischaemic attack (TIA). Perindopril-based blood pressure-lowering therapy was evaluated on Recurrent stroke. Blood pressure-lowering therapy reduced recurrent stroke in both normotensive and hypertensive patients with prior stroke or TIA.
Synapse has enriched 10 related papers. Consider them for comparative context: